AbCellera Biologics Inc.
Extracted from this filing and checked against the source text.
AbCellera Biologics Inc. shareholders approved Election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil. as Class III directors at the 2026-06-11 meeting.
The Company’s shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class III directors as follows: Nominee For Against Abstain John S. Montalbano, CFA 141,430,732 12,723,342 45,898 Stephen R. Quake, D.Phil. 149,019,960 5,113,056 66,956 The broker non-votes for this Proposal 1 totaled 36,576,359 common shares.View on SEC.gov
AbCellera Biologics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain 189,927,972 552,429 295,930View on SEC.gov
AbCellera Biologics Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers (Say-on-Pay) at the 2026-06-11 meeting.
The Company’s shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain 142,831,950 10,932,105 435,917 The broker non-votes for this Proposal 3 totaled 36,576,359 common shares.View on SEC.gov
1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.